<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697281</url>
  </required_header>
  <id_info>
    <org_study_id>OC000459/010/07</org_study_id>
    <nct_id>NCT00697281</nct_id>
  </id_info>
  <brief_title>OC000459 Dose Finding Study in Hay Fever Sufferers.</brief_title>
  <official_title>A Dose Finding Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxagen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxagen Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate a range of dose levels for efficacy in the
      control of symptoms of allergic rhinitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomised, double blind, placebo controlled, parallel group evaluation of
      OC000459 given orally for eight days. Four dose levels will be studied and compared to
      placebo. They will be studied in treatment groups of 18 to 21 subjects. The placebo group
      will also consist of 18 to 21 subjects. There will be a screening period of up to six weeks.
      There will be a follow up one to three weeks after the last dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total nasal symptom score (TNSS)</measure>
    <time_frame>After 8 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other symptom scores of allergic rhinitis</measure>
    <time_frame>After 8 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days
Dose level 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days
Dose level 2</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days
Dose level 3</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC000459</intervention_name>
    <description>Tablets twice daily for 8 days
Dose level 4</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets twice daily for 8 days
Dose level 5</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 50 years with a history of symptoms of grass pollen
             related allergic rhinitis within the previous two years.

          -  Females of childbearing potential (i.e. having had a menstrual period within two years
             prior to the date of screening) must practise two forms of contraception and must have
             a negative pregnancy test (blood or urine) at screening.

          -  Acceptable contraception includes the use of TWO of the following:

               -  oral contraception (i.e. the Pill);

               -  intrauterine device (an IUD or 'Coil');

               -  barrier contraception (i.e. condoms or diaphragm/cap);

               -  transdermal patch

        Exclusion Criteria:

          -  Medical conditions likely to affect the outcome of the study.

          -  Nasal conditions likely to affect the outcome of the study, i.e. nasal septal
             perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal
             diseases as determined by the principal investigator or designee.

          -  Presence of any respiratory disease other than a history of mild stable asthma not
             requiring treatment and associated with normal lung function (defined as FEV1 â‰¥ 90%
             predicted for height and age).

          -  Immunotherapy treatment course in the past 28 days

          -  Use of inhaled or local corticosteroids in the past 28 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Univ Prof. Dr. Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergie Zentrum Wien West</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergie Zentrum Wien West, Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <zip>1150 VIENNA</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr C Mike Perkins</name_title>
    <organization>Oxagen Ltd</organization>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>human</keyword>
  <keyword>clinical trial</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>challenge test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indoleacetic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

